67652000PCR3002/AMPLITUDE

Phase III
Appareil genital masculin, Prostate
Localement avancé ou métastatique 1ere ligne

Description de l’essai

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone (AA-P) and ADT Versus Abiraterone Acetate and Prednisone and ADT in Subjects With Metastatic Castration Sensitive Prostate Cancer (mCSPC) with DNA-repair gene defects

Trial sponsor

JANSSEN CILAG

Médecin ICO - Angers

SOPHIE ABADIE-LACOURTOISIE

Type d'intervention évaluée

Hormonothérapie ,Thérapies ciblées

Date de début de l'essai

10/06/2021